Szabo P, Macera M J, Verma R S
Department of Medicine, New York Hospital-Cornell Medical Center, New York.
Mol Biol Med. 1988 Dec;5(3):139-44.
In an attempt to further substantiate the involvement of the c-abl oncogene in the genesis of chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), we performed in-situ hybridization with the c-abl probe on metaphase chromosomes of a healthy control, a karyotypically normal non-CML leukemia, three cases of CML with t(9;22), t(13;22) and t(3;9;22), one blast phase CML with t(9;22), Ph, + Ph, and one ALL with t(9;22), Ph, + Ph. The aberrant 9q could be cytogenetically identified in all cases except t(13;22). The molecular data clearly demonstrated the involvement of the c-abl in t(13;22) and the karyotype was revised to t(9;13;22). All patients, except the control, showed the altered c-able/bcr rearrangement that has been demonstrated in the Ph-chromosome from the standard t(9;22) translocation. These findings suggest that genomic diversities have important clinical differences in these two diseases. The amalgamation of information from cytogenetic and molecular data on cases where translocations are not precise or difficult to identify, will lead towards a deeper understanding of leukemias.
为了进一步证实c-abl癌基因与慢性粒细胞白血病(CML)和急性淋巴细胞白血病(ALL)发生的相关性,我们用c-abl探针在一名健康对照、一名核型正常的非CML白血病患者、三例分别具有t(9;22)、t(13;22)和t(3;9;22)的CML患者、一例具有t(9;22)、Ph、+Ph的急变期CML患者以及一例具有t(9;22)、Ph、+Ph的ALL患者的中期染色体上进行了原位杂交。除了t(13;22)病例外,所有病例均可通过细胞遗传学方法鉴定出异常的9q。分子数据清楚地表明c-abl参与了t(13;22),核型被修订为t(9;13;22)。除对照外,所有患者均显示出c-abl/bcr重排改变,这已在标准t(9;22)易位的Ph染色体中得到证实。这些发现表明,基因组多样性在这两种疾病中具有重要的临床差异。将细胞遗传学和分子数据信息整合到易位不精确或难以识别的病例中,将有助于更深入地了解白血病。